Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic

Eur Respir J. 2022 Jul 28;60(1):2102333. doi: 10.1183/13993003.02333-2021. Print 2022 Jul.

Abstract

Background: Asthma is characterised by an aggravated immune response to respiratory viral infections. This phenomenon is a clinically well-recognised driver of acute exacerbations, but how different phenotypes of asthma respond immunologically to viruses is unclear.

Objectives: To describe the association between different phenotypes and severity of asthma and bronchial epithelial immune responses to viral stimulation.

Methods: In the Immunoreact study, healthy subjects (n=10) and 50 patients with asthma were included; 30 (60%) were atopic, and 34 (68%) were eosinophilic; 14 (28%) had severe asthma. All participants underwent bronchoscopy with collection of bronchial brushings. Bronchial epithelial cells (BECs) were expanded and stimulated with the viral replication mimic poly (I:C) (Toll-like receptor (TLR)3 agonist) in vitro. The expression of TLR3-induced pro-inflammatory and antiviral responses of BECs were analysed using reverse transcriptase quantitative PCR and multiplex ELISA and compared across asthma phenotypes and severity of disease.

Results: Patients with atopic asthma had increased induction of interleukin (IL)-4, interferon (IFN)-β, IL-6, tumour necrosis factor-α, and IL-1β after poly (I:C) stimulation compared to non-atopic patients, whereas in patients with eosinophilic asthma only IL-6 and IL-8 induction was higher than in non-eosinophilic asthma. Patients with severe asthma displayed a decreased antiviral IFN-β, and increased expression of IL-8, most pronounced in atopic and eosinophilic asthmatics. Furthermore, induction of IL-33 in response to poly (I:C) was increased in severe atopic and in severe eosinophilic asthma, but thymic stromal lymphopoietin only in severe eosinophilic asthma.

Conclusions: The bronchial epithelial immune response to a viral mimic stimulation differs between asthma phenotypes and severities, which may be important to consider when targeting novel asthma treatments.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Asthma* / drug therapy
  • Humans
  • Immunity
  • Interferon-beta / metabolism
  • Interferon-beta / therapeutic use
  • Interleukin-6
  • Interleukin-8*
  • Phenotype
  • Poly I-C / pharmacology

Substances

  • Antiviral Agents
  • Interleukin-6
  • Interleukin-8
  • Interferon-beta
  • Poly I-C